The FDA has officially ended the Clozapine REMS program—meaning no more mandatory registration, reporting, or ANC submissions to the REMS system! 🙌
What does this mean?
✅ Prescribers – No more REMS hurdles, but ANC monitoring is still recommended.
✅ Pharmacies – No REMS verification needed before dispensing.
✅ Patients – No more REMS-related delays in getting your medication!
This long-awaited change follows input from an FDA advisory committee and aims to reduce unnecessary barrierswhile keeping clozapine use safe and effective.
💬 What are your thoughts on this update? Drop a comment below! 👇
Leave a Reply